Journal
CANCER TREATMENT REVIEWS
Volume 110, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2022.102460
Keywords
Colorectal cancer; Regorafenib; Immune checkpoint inhibitors; Microsatellite stable; Mismatch repair proficient
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy in cancer treatment, but their therapeutic potential in colorectal cancer is limited. Previous studies have focused on strategies to overcome resistance to ICIs, and the combination of ICIs with multi-kinase inhibitors is being widely investigated. Multi-kinase inhibitors can synergistically enhance the recognition and targeting of cancer cells by the immune system.
Immune checkpoint inhibitors (ICIs) have marked a new era of cancer treatment, showing remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC), however, the therapeutic potential of ICIs is limited to the small group (R-.15%) of patients with mismatch repair deficient (dMMR)/high microsatellite instable (MSI-H) tumours, which are characterised by high mutational/neo-antigen burden, and an inflammatory tumour microenvironment with abundant tumour-infiltrating lymphocytes. Over the last few years, research has focused on immuno-modulatory strategies that could overcome the inherent resistance to ICIs that is observed in the vast group (R-.195%) of patients with mismatch repair proficient (pMMR)/microsatellite stable (MSS) tumours. Among these, the combination of ICIs with multi-kinase inhibitors has gained traction in preclinical studies and clinical trials. Thanks to their multiple targets and mechanisms of action, generally involving key cancer pathways such as oncogenesis, angiogenesis, metastasis, and tumour immunity, these agents can exert synergistic effects with ICIs, eventually turning inherently cold cancers into hot tumours, that can be efficiently recognised and targeted by an activated immune system. Regorafenib is routinely used for chemorefractory CRC with limited efficacy. Preliminary evidence, however, suggests that this multi-kinase inhibitor could be an optimal combination partner for ICIs. In this review article, we explain the biological rationale underlying the synergism between regorafenib and ICIs, discuss the available clinical data in CRC, and take a glance into future perspectives by presenting ongoing trials and possible research developments in this setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available